People with health issues or inactivated vaccine should get COVID-19 booster: WHO
Health body says vaccines provide robust protection against disease for at least 6 months
Geneva: The World Health Organisation (WHO) recommended on Thursday that people who are immunocompromised or received an inactivated COVID-19 vaccine should receive a booster dose to protect against waning immunity.
Many countries have been rolling out booster shots, targeting the elderly and people with underlying health issues, but worries about the new, more transmissible Omicron variant have prompted some to expand their use to larger portions of their populations.
With vaccination rates worryingly low in much of the developing world, the WHO has said in recent months that administering primary doses - rather than boosters - should be a priority.
The recommendation comes after the Strategic Advisory Group of Experts (SAGE) on immunisation held a meeting on Tuesday to evaluate the need for COVID-19 boosters and was largely in line with guidance given in October.
Speaking in a briefing, SAGE chair Alejandro Cravioto said vaccines provide a robust level of protection against severe disease for at least six months, although data shows immunity wanes against severe disease in older adults and those with underlying health conditions.
“For the time being we continue to support the need for equity in distribution (of vaccines) and the use of a third dose only in those” with health problems or people who have received an inactivated vaccine, he said.
COVID-19 vaccines protect “very well” through six months after the last dose with some “minor, modest reduction” in protection, Kate O’Brien, director of the WHO’s immunisation department, said.
Inactivated vaccines that take the SARS-CoV-2 virus and inactivate or kill it using chemicals, heat or radiation are made by Chinese manufacturers Sinovac Biotech, state-owned Sinopharm and India’s Bharat Biotech.
They have been granted emergency use approval by the WHO.
The WHO executives did not name the vaccines in Thursday’s briefing.
A single dose of the Johnson & Johnson vaccine is still effective, but data from the company’s clinical trials using two doses clearly show the benefit of having further vaccination, Cravioto said on Thursday.